V

ViroGates A/S
CSE:VIRO

Watchlist Manager
ViroGates A/S
CSE:VIRO
Watchlist
Price: 15.4 DKK -6.67% Market Closed
Market Cap: 119.1m DKK
Have any thoughts about
ViroGates A/S?
Write Note

ViroGates A/S
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ViroGates A/S
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
V
ViroGates A/S
CSE:VIRO
Income from Continuing Operations
-kr13.2m
CAGR 3-Years
10%
CAGR 5-Years
6%
CAGR 10-Years
N/A
GN Store Nord A/S
CSE:GN
Income from Continuing Operations
kr706m
CAGR 3-Years
-28%
CAGR 5-Years
-12%
CAGR 10-Years
0%
Ambu A/S
CSE:AMBU B
Income from Continuing Operations
kr235m
CAGR 3-Years
-2%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Demant A/S
CSE:DEMANT
Income from Continuing Operations
kr2.7B
CAGR 3-Years
6%
CAGR 5-Years
9%
CAGR 10-Years
8%
No Stocks Found

ViroGates A/S
Glance View

Market Cap
119.1m DKK
Industry
Health Care

ViroGates A/S develops and markets prognostic products for the healthcare sector. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.

VIRO Intrinsic Value
3.42 DKK
Overvaluation 78%
Intrinsic Value
Price
V

See Also

What is ViroGates A/S's Income from Continuing Operations?
Income from Continuing Operations
-13.2m DKK

Based on the financial report for Sep 30, 2024, ViroGates A/S's Income from Continuing Operations amounts to -13.2m DKK.

What is ViroGates A/S's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
6%

Over the last year, the Income from Continuing Operations growth was -25%. The average annual Income from Continuing Operations growth rates for ViroGates A/S have been 10% over the past three years , 6% over the past five years .

Back to Top